Upsher-Smith launches generic Tegretol
The carbamazepine extended-release tablet had a market value of roughly $120 million for the 12 months ended June 2021, according to IQVIA.
A new generic product is making its debut from Upsher-Smith.
The company is launching carbamazepine extended-release tablets, which are available in three dosage strengths — 100 mg, 200 mg and 400 mg.
Upsher-Smith’s product is the generic version of Novartis’ Tegretol XR (carbamazepine extended-release tablets).
The medication is an anticonvulsant and specific analgesic for trigeminal neuralgia.
The carbamazepine extended-release tablet market had a market value of roughly $120 million for the 12 months ended June 2021, according to IQVIA.